PAVmed earnings release, August 14, 2026
Exhibit
99.1
PAVmed
Provides Business Update and Reports Second Quarter 2026 Financial Results
Veris
Health accelerated its commercial engagement with OSU-The James
Veris
Health implantable physiological monitor achieved development milestones towards upcoming FDA submission
Lucid
Diagnostics secured first laboratory benefit manager coverage policy for
EsoGuard®
Conference call and webcast to be held today, August 14, at 8:30 AM EDT
NEW
YORK, August 14, 2026 -
PAVmed Inc. (NASDAQ: PAVM) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD)
(“Lucid”),
Veris Health Inc. (“Veris”), and Octeris Medical Inc. (“Octeris”), and reported financial results for the second quarter ended June 30, 2026.
Conference
Call and Webcast
The webcast will take place on Friday, August 14, 2026, at 8:30 AM and is accessible in the investor relations section of the Company’s website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name “PAVmed
Business Update” to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company’s website at pavmed.com.
Business
Update Highlights
“PAVmed saw tangible progress across its core businesses during this past quarter and recent weeks,” said
Lishan Aklog, M.D.,
PAVmed’s Chairman and Chief Executive Officer. “Veris accelerated its commercial engagement with OSU-The James while progressing development of its implantable physiological monitor toward FDA submission.
Lucid secured an important new commercial coverage policy for EsoGuard while continuing to advance its broader commercial initiatives. And, our relaunched medical device portfolio is on track with
PortIO and Octeris progressing toward key milestones.”
Highlights from the second quarter and recent weeks
:
Financial
Results
:
PAVmed
Non-GAAP Measures¹
Included in general and administrative expenses in the financial statements.²
Included in other income and expenses.³
Stock-based compensation (“SBC”) expense is included in operating expenses and is detailed as follows in the table below by category within operating expenses for the non-GAAP Net operating expenses:
About
PAVmed and its Subsidiaries
PAVmed
Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors.
Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard®
Esophageal DNA Test and EsoCheck®
Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the
Veris Cancer Care Platform.
For more information about PAVmed, please visit pavmed.com.
For more information about Lucid Diagnostics, please visit luciddx.com.
For more information about Veris Health, please visit verishealth.com.
Forward-Looking
Statements
Financial statements
Income Statement
For the three months ended June 30, — PAVmed Non-GAAP Measures (in thousands except per-share amounts)
| For the three months ended June 30, – 2026 | For the three months ended June 30, – 2025 | For the six months ended June 30, – 2026 | For the six months ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| (in thousands except per-share amounts) | Revenue | 33 | 6 | 55 | 14 |
| (in thousands except per-share amounts) | Operating expenses | 7,055 | 4,721 | 15,112 | 10,174 |
| (in thousands except per-share amounts) | Other (Income) Expense, net | -424 | 7,609 | -7,395 | -16,460 |
| (in thousands except per-share amounts) | Net (Income) Loss | 6,598 | 12,324 | 7,662 | -6,300 |
| (in thousands except per-share amounts) | Net income (loss) per common share, diluted | -0.87 | -22.08 | -3.17 | 3.94 |
| (in thousands except per-share amounts) | Net income (loss) attributable to common stockholders | -5,479 | -13,308 | -12,467 | 4,386 |
| (in thousands except per-share amounts) | Preferred Stock dividends and deemed dividends | 95 | 1,387 | 7,023 | 2,661 |
| (in thousands except per-share amounts) | Net income (loss) as reported | -5,384 | -11,921 | -5,444 | 7,047 |
| Adjustments: | Depreciation and amortization expense1 | 19 | 22 | 39 | 65 |
| Adjustments: | Interest expense, net2 | -8 | -4 | -24 | -7 |
| Adjustments: | NCI ownership share of Interest and Depreciation adjustments | -256 | -507 | ||
| Adjustments: | EBITDA | -5,629 | -11,903 | -5,936 | 7,105 |
| Other non-cash or financing related expenses: | Stock-based compensation expense3 | 917 | 162 | 1,099 | 1,092 |
| Other non-cash or financing related expenses: | Operating expenses issued in stock1 | 53 | 1,951 | 103 | |
| Other non-cash or financing related expenses: | Change in FV equity method investments | 2,504 | 10,643 | 626 | -10,361 |
| Other non-cash or financing related expenses: | Change in FV convertible debt2 | 565 | 200 | -2,795 | 249 |
| Other non-cash or financing related expenses: | Loss on debt extinguishment2 | 3,422 | 58 | ||
| Other non-cash or financing related expenses: | Change in fair value – warrant liability | -1,831 | |||
| Other non-cash or financing related expenses: | Change in fair value – rights liability | -24 | -54 | ||
| Other non-cash or financing related expenses: | Non-GAAP adjusted (loss) | -1,667 | -845 | -3,518 | -1,754 |
| Other non-cash or financing related expenses: | Non-GAAP shares outstanding, basic and diluted | 6,269 | 603 | 3,938 | 533 |
| Other non-cash or financing related expenses: | Non-GAAP adjusted (loss) income per share, basic and diluted | -0.27 | -1.4 | -0.89 | -3.29 |
Income Statement
For the three months ended June 30, (in thousands except per-share amounts)
| For the three months ended June 30, – 2026 | For the three months ended June 30, – 2025 | For the six months ended June 30, – 2026 | For the six months ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| (in thousands except per-share amounts) | Cost of revenue | 122 | 41 | 219 | 78 |
| (in thousands except per-share amounts) | Net cost of revenue | 122 | 41 | 219 | 78 |
| (in thousands except per-share amounts) | Sales and marketing | 215 | 220 | 430 | 467 |
| (in thousands except per-share amounts) | Stock-based compensation expense3 | -8 | -1 | -13 | -46 |
| (in thousands except per-share amounts) | Net sales and marketing | 207 | 219 | 417 | 421 |
| (in thousands except per-share amounts) | General and administrative | 4,651 | 3,670 | 11,008 | 8,053 |
| (in thousands except per-share amounts) | Depreciation expense | -19 | -22 | -39 | -65 |
| (in thousands except per-share amounts) | Operating expenses issued in stock | -53 | -1,951 | -103 | |
| (in thousands except per-share amounts) | Stock-based compensation expense3 | -874 | -148 | -1,029 | -944 |
| (in thousands except per-share amounts) | Net general and administrative | 3,758 | 3,447 | 7,989 | 6,941 |
| (in thousands except per-share amounts) | Research and development | 2,067 | 790 | 3,455 | 1,576 |
| (in thousands except per-share amounts) | Stock-based compensation expense3 | -35 | -13 | -57 | -102 |
| (in thousands except per-share amounts) | Net research and development | 2,032 | 777 | 3,398 | 1,474 |
| (in thousands except per-share amounts) | Total operating expenses | 7,055 | 4,721 | 15,112 | 10,174 |
| (in thousands except per-share amounts) | Depreciation and amortization expense | -19 | -22 | -39 | -65 |
| (in thousands except per-share amounts) | Operating expenses issued in stock | -53 | -1,951 | -103 | |
| (in thousands except per-share amounts) | Stock-based compensation expense3 | -917 | -162 | -1,099 | -1,092 |
| (in thousands except per-share amounts) | Net operating expenses | 6,119 | 4,484 | 12,023 | 8,914 |
Full release
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed’s and Lucid’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed’s and Lucid’s common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed’s and Lucid’s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed’s and Lucid’s clinical and preclinical studies; whether and when PAVmed’s and Lucid’s products are cleared by regulatory authorities; market acceptance of PAVmed’s and Lucid’s products once cleared and commercialized; PAVmed’s and Lucid’s ability to raise additional funding as needed; and other competitive developments. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed’s and Lucid’s future operations, see Part I, Item 1A, “Risk Factors,” in PAVmed’s and Lucid’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report. PAVmed and Lucid disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on... (truncated)ions may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
Investor and Media Contact
Matt
Riley
Vice
President
PAVmed and Lucid Diagnostics mjr@pavmed.com